Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New $2.6bn NEA venture fund could invest $650m in biopharma

This article was originally published in Scrip

Executive Summary

Up to $650 million from New Enterprise Associates' $2.6 billion venture capital fund could be invested in biopharmaceutical opportunities. NEA health care practice head and general partner David Mott told Scrip that an estimated one-third of NEA's 14th venture fund would be dedicated to health care with two-thirds to three-quarters of that portion invested in biopharma companies.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018251

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel